Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425349 | 0.96 | EGFR (0.45) | EGFRERBB3TP53TGFBR1ACVRL1 | |
| SCHEMBL12425348 | 0.95 | EGFR (0.40) | EGFRERBB3TP53TGFBR1ACVRL1 | |
| SCHEMBL12424683 | 0.90 | EGFR (0.39) | EGFRERBB3TP53TGFBR1ACVRL1 | |
| SCHEMBL12424827 | 0.89 | ACP1 (0.39) | EGFRERBB3TP53TGFBR1ACVRL1 | |
| SCHEMBL12426284 | 0.88 | IGF1R (0.41) | EGFRERBB3TP53TGFBR1ACVRL1 | |
| SCHEMBL12424774 | 0.88 | IGF1R (0.40) | EGFRERBB3TP53TGFBR1ACVRL1 | |
| SCHEMBL12426286 | 0.87 | IGF1R (0.39) | EGFRERBB3TP53TGFBR1ACVRL1 | |
| SCHEMBL12424769 | 0.87 | ACHE (0.38) | EGFRERBB3TP53 | |
| SCHEMBL12424841 | 0.86 | ACVR1B (0.45) | EGFRERBB3TGFBR1ACVRL1ADORA3 | |
| SCHEMBL12425340 | 0.86 | IGF1R (0.41) | EGFRERBB3TGFBR1ACVRL1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | EGFR 846/4885ERBB3 542/4885TP53 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.